Valeant Pharmaceuticals International Inc Raises FY 2013 Guidance


Thursday, 31 Oct 2013 06:00am EDT 

Valeant Pharmaceuticals International Inc updated its fiscal 2013 guidance and expects Cash earnings per share (EPS) to be in the range of $6.11 to $6.16, total revenue for 2013 to be in the range of $5.7 billion to $5.9 billion. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $6.14 on revenues of $5.9 billion for fiscal 2013.